SLC25A19 is a novel prognostic biomarker related to immune invasion and ferroptosis in HCC
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The mitochondrial thiamine pyrophosphate carrier SLC25A19 is highly expressed in hepatocellular carcinoma (HCC), predicting poor prognosis. Silencing SLC25A19 inhibits cancer growth and induces ferroptosis, suggesting it as a therapeutic target.
Area Of Science
- Molecular Biology
- Oncology
- Metabolic Diseases
Background
- SLC25A19, a mitochondrial thiamine pyrophosphate (TPP) carrier, is implicated in metabolic diseases.
- Its specific role in cancer, particularly hepatocellular carcinoma (HCC), remains under-investigated.
Purpose Of The Study
- To investigate the expression, prognostic value, and functional role of SLC25A19 in HCC.
- To explore the association of SLC25A19 with immune infiltration and ferroptosis in HCC.
Main Methods
- Analysis of The Cancer Genome Atlas (TCGA) clinical data for SLC25A19 expression, enrichment, immune infiltration, ferroptosis, and prognosis in HCC.
- In vitro validation using qRT-PCR, immunohistochemistry, CCK8, EdU, clone formation, trans-well, and scratch assays.
- Detection of ferroptosis-related indicators.
Main Results
- SLC25A19 is highly expressed in HCC and correlates with advanced tumor stage, poor pathological status, and elevated AFP, predicting a poor prognosis.
- SLC25A19 expression is significantly associated with immune infiltration, fatty acid metabolism, and ferroptosis.
- In vitro, SLC25A19 knockdown suppressed HCC cell proliferation and migration while inducing ferroptosis.
Conclusions
- SLC25A19 serves as a novel prognostic biomarker in HCC, linked to immune invasion and ferroptosis.
- SLC25A19 represents a potential therapeutic target for HCC treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...